IL-6 and ovarian cancer - Response

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7838-

  Balkwill, Frances R ^a   Coward, Jermaine ^a   Kulbe, Hagen ^a   Milagre, Carla ^a   Gopinathan, Ganga ^a   McNeish, Iain A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; JAGGED1; PACLITAXEL; SILTUXIMAB; VASCULOTROPIN;

ADVANCED CANCER; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

EID: 84055176210     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2680     Document Type: Letter

References (6)

1. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin- 6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010;16:3028-34.
2. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083-96.
3. Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481-94.
4. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83.
5. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011;71:424-34.
6. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010;119: 451-6.